Anthem Biosciences IPO open date is July 14, 2025 and the IPO will close on July 16, 2025. Anthem Biosciences IPO is a Book Build Issue. The company to raise around ₹3,395 crores via IPO that comprises fresh issue of ₹[.] crores and offer for sale up to 5,95,61,404 equity shares with face value of ₹2 each.
Anthem Biosciences IPO price band is ₹540 to ₹570 per share. The retail quota is 35%, QIB is 50%, and HNI is 15%. Anthem Biosciences IPO to list on BSE, NSE on July 21, 2025. The allotment of Anthem Biosciences IPO date is July 17, 2025.
The company reported revenue of ₹1,930.29 crores in 2025 against ₹1,483.07 crore in 2024. The company reported profit of ₹451.26 crores in 2025 against profit of ₹367.31 crores in 2024. As per the financials the IPO investors should apply the IPO for a long term.
Anthem Biosciences IPO Details
| IPO Open Date: | July 14, 2025 |
| IPO Close Date: | July 16, 2025 |
| Face Value: | ₹2 Per Equity Share |
| IPO Price Band: | ₹540 to ₹570 Per Share |
| Issue Size: | Approx ₹3,395 Crores |
| Offer for Sale: | Approx 5,95,61,404 Equity Shares |
| Issue Type: | Book Build Issue |
| IPO Listing: | BSE & NSE |
| Retail Quota: | Not more than 35% |
| QIB Quota: | Not more than 50% |
| NII Quota: | Not more than 15% |
| DRHP Draft Prospectus: | Click Here |
| RHP Draft Prospectus: | Click Here |
| Anchor Investors List: | Click Here |
Anthem Biosciences IPO Market Lot
The Anthem Biosciences IPO minimum market lot is 26 shares with ₹14,820 application amount. The retail investors can apply up-to 13 lots with 338 shares of ₹1,92,660 amount.
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 1 | 26 | ₹14,820 |
| Retail Maximum | 13 | 338 | ₹1,92,660 |
| S-HNI Minimum | 14 | 364 | ₹2,07,480 |
| B-HNI Minimum | 68 | 1,768 | ₹10,07,760 |
Anthem Biosciences IPO Dates
The Anthem Biosciences IPO date is July 14 and the close date is July 16. The Anthem Biosciences IPO allotment will be finalized on July 17 and the IPO listing on July 21.
| IPO Open Date: | July 14, 2025 |
| IPO Close Date: | July 16, 2025 |
| Basis of Allotment: | July 17, 2025 |
| Refunds: | July 18, 2025 |
| Credit to Demat Account: | July 18, 2025 |
| IPO Listing Date: | July 21, 2025 |
Promoters of Anthem Biosciences IPO
The promoters of the company are Ajay Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa and Ishaan Bhardwaj.
About Anthem Biosciences IPO
Anthem Biosciences Limited, established in 2006, is one of the emerging innovation-driven and technology-focused Contract Research, Development and Manufacturing Organizations (“CRDMO”) with end-to-end operations covering drug discovery, development and manufacturing. Anthem Biosciences is one of the few companies in India with integrated capabilities across new chemical entities (NCEs) and new biological entities (NBEs) across drug discovery, development and commercial manufacturing.
Anthem Biosciences is a one-stop service provider engaged in serving a wide range of customers including emerging biotechnology companies and large pharmaceutical companies across the globe. The company is engaged in manufacturing niche fermentation-based APIs including probiotics, enzymes, peptides, nutritional active substances, vitamin analogs and biosimilars. The company has supplied to over 150 customers ranging from small biotechs to large pharmaceutical companies as of March 31, 2024. Currently, the company has a team of 600 employees, including medicinal chemists, microbiologists, molecular biologists, biochemists and chemical engineers.
Anthem Biosciences IPO Company Financial Report
The company reported revenue of ₹1,930.29 crores in 2025 against ₹1,483.07 crore in 2024. The company reported profit of ₹451.26 crores in 2025 against profit of ₹367.31 crores in 2024.
Amount ₹ in Crores
| Period Ended | Revenue | Expense | Profit After Tax | Assets |
| 2022 | ₹1,280.24 | ₹734.10 | ₹405.54 | ₹1,618.87 |
| 2023 | ₹1,133.99 | ₹698.50 | ₹385.19 | ₹2,014.46 |
| 2024 | ₹1,483.07 | ₹1,005.75 | ₹367.31 | ₹2,398.11 |
| 2025 | ₹1,930.29 | ₹1,273.42 | ₹451.26 | ₹2,807.58 |
Anthem Biosciences IPO Valuation – FY2025
| KPI | Values |
| ROE: | 20.82% |
| ROCE: | 27.64% |
| EBITDA Margin: | 36.81% |
| PAT Margin: | 23.38% |
| Debt to equity ratio: | 0.05 |
| Earning Per Share (EPS): | ₹8.07 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 20.82% |
| Net Asset Value (NAV): | ₹43.10 |
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Syngene International Limited | 12.35 | 51.54 | 11.05% | 117.42 | 3,642.40 Cr. |
| Sai Life Sciences Limited | 8.83 | 92.18 | 10.96% | 102.12 | 1,694.57 Cr. |
| Suven Life Sciences Limited | 10.52 | 97.29 | 13.61% | 72.31 | 1,197.58 Cr. |
| Divi’s Laboratories Limited | 82.53 | 83.22 | 15.35% | 564.87 | 9,360.00 Cr. |
Objects of the Issue
- The Company will not receive any proceeds from the Offer (the “Offer Proceeds”) and all the Offer Proceeds will be received by the Selling Shareholders after deduction of Offer related expenses and relevant taxes thereon, to be borne by the respective Selling Shareholders.